MedTrace Logo

Long Antagonist Protocol for IVF With Single Luteal Dose of Degarelix

NCT03240159 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 120

Last updated 2020-10-08

No results posted yet for this study

Summary

A prospective study of three different doses of Degarelix in late luteal phase of women undergoing ovarian stimulation for IVF

Conditions

  • Pregnancy, Ovarian

Interventions

DRUG

Degarelix

Degarelix 24mg Degarelix 16mg Degarelix 12mg Active Comparator: Down regulation of LH, during exposing in three different doses of Degarelix

Sponsors & Collaborators

  • Assisting Nature

    lead OTHER

Principal Investigators

  • Evaggelos Papanikolaou, MD, PhD · Assisting Nature

  • Robert Najdecki, MD, PhD · Assisting Nature

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
39 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-02-15
Primary Completion
2021-06-30
Completion
2021-06-30

Countries

  • Greece

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03240159 on ClinicalTrials.gov